Genetic test predicts response to weight-loss drugs
September 18, 2025
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.
Researchers from the University of Birmingham’s Bladder Cancer Research Center have used a new method to detect chemical changes in the DNA in an individual’s urine sample; epigenetic changes, called methylation.
Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice and humans. In mice, a team led by Michael Kaminski was able to ease a key symptom of the difficult-to-treat disease.
A researcher at the Hackensack Meridian Center for Discovery and Innovation (CDI) and physician-scientist colleagues from Hackensack Meridian Health have shown how a critical pathway is fundamental to the immune system.
Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, a potential breakthrough that could allow easier, community-based screenings for the world’s deadliest infectious disease.
Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help researchers—even those unfamiliar with gene editing—generate designs, analyze data and troubleshoot design flaws.
Advance from SMART will help to better identify disease markers and develop targeted therapies and personalized treatment for diseases such as cancer and antibiotic-resistant infection.
Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection (tearing) and death in childhood. Currently, there is no effective treatment or cure for MSMDS.
Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia, according to two studies published in Blood Advances.
Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their highly effective vaccines to fight the virus.